Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

Sophie, Raafay; Moses, Giovanna M.; Hwang, Eileen S.; Kim, Judy E.

doi:10.1001/jamaophthalmol.2019.0970

Cited by 11 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently, a case of fundus hypopigmentation and loss of choroidal naevi pigmentation has been reported in association with nivolumab. However, in contrast to our case, the fundus changes appeared as unilateral yellowish spots around the optic nerve (Sophie et al 2019). To our knowledge, the present case report is the first to show that PD-1 inhibitor monotherapy can lead to diffuse hypopigmentation of both fundi and regression of a pre-existing choroidal naevus.…”

Section: Choroidal Naevus Regression Associated Withcontrasting

confidence: 93%

Choroidal naevus regression associated with PD‐1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

Krohn

Hanken

Herlofsen³

2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Section: Choroidal Naevus Regression Associated Withcontrasting

confidence: 93%

Choroidal naevus regression associated with PD‐1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

Krohn

Hanken

Herlofsen³

2019

Acta Ophthalmologica

View full text Add to dashboard Cite

“…These findings seem to be induced by an immune-mediated reaction against self-melanocytes, like in VKH like uveitis. But unlike VKH disease, there is no inflammation of the eye [ 182 – 184 ].…”

Section: Discussionmentioning

confidence: 99%

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

Martens

Schauwvlieghe

Madoe

et al. 2023

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Introduction Immune checkpoint inhibitors (ICIs) have become an important part of the treatment of multiple cancers, especially for advanced melanoma and non-small cell lung cancer. Some tumors are capable of escaping immunosurveillance by stimulating checkpoints on T-cells. ICIs prevent activation of these checkpoints and thereby stimulate the immune system and indirectly the anti-tumor response. However, the use of ICIs is associated with various adverse events. Ocular side effects are rare but may have a major impact on the quality of life of the patient. Methods A comprehensive literature search of the medical databases Web of Science, Embase and PubMed was performed. Articles that provided a comprehensive description of a case report containing 1) cancer patient(s) treated with (a combination of) immune checkpoint inhibitors, and 2) assessed occurrence of ocular adverse events, were included. A total of 290 case reports were included. Results Melanoma (n = 179; 61.7%) and lung cancer (n = 56; 19.3%) were the most frequent reported malignancies. The primary used ICIs were nivolumab (n = 123; 42.5%) and ipilimumab (n = 116; 40.0%). Uveitis was most the common adverse event (n = 134; 46.2%) and mainly related to melanoma. Neuro-ophthalmic disorders, including myasthenia gravis and cranial nerve disorders, were the second most common adverse events (n = 71; 24.5%), mainly related to lung cancer. Adverse events affecting the orbit and the cornea were reported in 33 (11.4%) and 30 cases (10.3%) respectively. Adverse events concerning the retina were reported in 26 cases (9.0%). Conclusion The aim of this paper is to provide an overview of all reported ocular adverse events related to the use of ICIs. The insights retrieved from this review might contribute to a better understanding of the underlying mechanisms of these ocular adverse events. Particularly, the difference between actual immune-related adverse events and paraneoplastic syndromes might be relevant. These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs.

show abstract

Exogen bedingte Retinopathien

Kellner,

Weinitz

et al. 2023

Springer Reference Medizin

View full text Add to dashboard Cite

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

Cited by 11 publications

References 8 publications

Choroidal naevus regression associated with PD‐1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

Choroidal naevus regression associated with PD‐1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

Exogen bedingte Retinopathien

Contact Info

Product

Resources

About